Library›Plants and preparation›Kava

Kava

Kava (Piper methysticum) is a Piperaceae shrub of the Pacific Islands whose root is prepared as a ceremonial and social beverage across Fiji, Vanuatu, Tonga, Samoa and Hawai'i. Its actives are the kavalactones — principally kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin.

Yangonin and the endocannabinoid connection

Yangonin is the kavalactone of interest to the Cannabinoid Oilahuasca framework. It is a FAAH inhibitor — slowing the breakdown of anandamide — and additionally has CB1 binding affinity of its own. That combination, a direct receptor interaction plus inhibition of the enzyme that clears the endogenous ligand, is unusual in a plant compound and is a substantial part of why kava's anxiolytic effect does not look like the sedative-hypnotic profile it superficially resembles.

Kava is one of two Piperaceae members carrying FAAH activity, the other being black pepper via guineensine.

Pharmacology beyond yangonin

Kavalactones as a group act on GABA-A (positive modulation, though not at the benzodiazepine site), voltage-gated sodium and calcium channels, and MAO-B; several are reported to inhibit noradrenaline reuptake. The anxiolytic effect in human trials is among the better-supported findings for any anxiolytic botanical.

Preparation matters, and it matters medically

Traditional preparation is a water extraction of the peeled root (rhizome). Two departures from that are implicated in kava's safety record:

• Acetonic and ethanolic extracts pull a different compound profile than water does.
• Aerial parts and root bark contain pipermethystine and flavokavain B, both hepatotoxic in vitro, and are excluded from traditional preparation. Their inclusion in some commercial material is a leading hypothesis for the hepatotoxicity cases.

The Potentiation Thesis

In ethnobotanical pharmacology, kava is often paired with metabolic and receptor synergists (the Oilahuasca framework applied to kavalactones). Black pepper serves as a quadruple-action synergist (piperine for CYP inhibition, guineensine for endocannabinoid reuptake, and β-caryophyllene for CB2 agonism). However, stacking deliberate CYP inhibitors onto kava introduces severe liver risks by slowing the clearance of the very compounds loading the liver. For the comprehensive mechanism map, five potentiator categories, and liver safety rules, see Kava Potentiation.

Cautions

Hepatotoxicity is the central issue with kava and it is not fully resolved. Case reports of severe liver injury led to bans or restrictions in Germany, Switzerland, France, Canada and the UK from 2002 onward; several were subsequently relaxed after review, and the WHO assessment attributed much of the risk to non-traditional preparations and to plant parts excluded from traditional use. The honest position is that traditional water-extracted peeled-root preparation has a far better record than the extracts that caused the cases, and that this does not amount to a clean bill of health.

• Avoid with alcohol and with other hepatically stressful agents.
• Avoid with hepatotoxic medication, and in existing liver disease.
• Kava inhibits several CYP450 enzymes — CYP2E1 notably, with reported effects at 1A2, 2C9, 2C19, 2D6 and 3A4 — so pharmacokinetic interactions with a wide range of medication are expected. In poly-herbal and Oilahuasca frameworks, kavalactones are sequenced specifically for this CYP inhibition; see Shulgin Ten Essential Amphetamines and Metabolic Chemistry.
• Additive with benzodiazepines, alcohol and other CNS depressants.
• Driving is affected.
• Kava dermopathy — a reversible dry, scaly rash — follows heavy chronic use.

See also: Kava Potentiation · FAAH · Cannabinoid Oilahuasca · Shulgin Ten Essential Amphetamines and Metabolic Chemistry · Endocannabinoid Chemistry and 2-AG Metabolism · Black Pepper · Stack Substances

Filed under  Plants and preparation

Elsewhere: Wikidata · Wikipedia